ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s ...
Michael Ingram is a Senior Contributor from the United States of America. Michael has been writing for GameRant since 2021 with a previous history of personal analytical writing. Michael is a lifelong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback